Białko mitochondrialne CMPK2 reguluje tworzenie
Białko mitochondrialne CMPK2 reguluje tworzenie komórek piankowatych wzmocnionych przez IFN alfa, potencjalnie przyczyniając się do przedwczesnej miażdżycy tętnic w SLE
Background: Untimely atherosclerosis happens in sufferers with SLE; nonetheless, the mechanisms stay unclear. Each mitochondrial equipment and proinflammatory cytokine interferon alpha (IFN-α) probably contribute to atherogenic processes in SLE. Right here, we discover the roles of the mitochondrial protein cytidine/uridine monophosphate kinase 2 (CMPK2) in IFN-α-mediated pro-atherogenic occasions.
Strategies: Foam cell measurements have been carried out by oil purple O staining, Dil-oxLDL uptake and the BODIPY strategy. The mRNA and protein ranges have been measured by qPCR and Western blotting, respectively. Isolation of CD4+ T cells and monocytes was carried out with monoclonal antibodies conjugated with microbeads. Manipulation of protein expression was performed by both small interference RNA (siRNA) knockdown or CRISPR/Cas9 knockout. The expression of mitochondrial reactive oxygen species (mtROS) was decided by circulate cytometry and confocal microscopy.
Outcomes: IFN-α enhanced oxLDL-induced foam cell formation and Dil-oxLDL uptake by macrophages. Along with IFN-α, a number of triggers of atherosclerosis, together with thrombin and IFN-γ, can induce CMPK2 expression, which was elevated in CD4+ T cells and CD14+ monocytes remoted from SLE sufferers in comparison with these remoted from controls. The evaluation of mobile subfractions revealed that CMPK2 was current in each mitochondrial and cytosolic fractions. IFN-α-induced CMPK2 expression was inhibited by Janus kinase (JAK)half of and tyrosine kinase 2 (Tyk2) inhibitors. Each the knockdown and knockout of CMPK2 attenuated IFN-α-mediated foam cell formation, which concerned the discount of scavenger receptor class A (SR-A) expression. CMPK2 additionally regulated IFN-α-enhanced mtROS manufacturing and inflammasome activation.
Conclusions: The research means that CMPK2 performs contributing roles within the pro-atherogenic results of IFN-α.
Goat Anti-Rabbit IgG(H+L) Alexa Fluor 594–conjugated |
|||
| S0006 | Affbiotech | 200ul | EUR 376 |
Donkey Anti-Goat IgG (H+L), Alexa Fluor® 594 Conjugated |
|||
| Ab8011-001 | GenDepot | 1mg | EUR 334 |
Donkey anti Goat IgG (H + L) (Fab 2) (Alexa Fluor 594) |
|||
| 43R-ID012AF | Fitzgerald | 300 ug | EUR 410 |
|
Description: Donkey anti Goat IgG (H + L) secondary antibody (Fab'2) (Alexa Fluor 594) |
|||
AF594-streptavidin conjugate [Streptavidin, Alexa Fluor™ 594 Conjugate] |
|||
| 16892 | AAT Bioquest | 1 mg | EUR 176 |
AF594 Phalloidin [equivalent to Alexa Fluor® 594 phalloidin] |
|||
| 23158 | AAT Bioquest | 300 Tests | EUR 306 |
Tubulin Beta-4A Chain (TUBB4) Antibody |
|||
| abx145781-100ug | Abbexa | 100 ug | EUR 391 |
Tubulin Beta-4A Chain (TUBB4) Antibody |
|||
| abx145784-100ug | Abbexa | 100 ug | EUR 391 |
Anti-RPSA Alexa Fluor® 488 |
|||
| A4-829-C100 | ExBio | 0.1 mg | EUR 310 |
Anti-CD40 antibody (Alexa-fluor 488) |
|||
| STJ170000 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: CD40 (48 to 50 kDa) is a transmembrane glycoprotein mainly expressed on the surface of B cells and also expressed on monocytes, dendritic cells, and thymic epithelium. CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily, which includes the low affinity nerve growth factor (NGF) receptor and CD95/Fas. CD40 is the receptor for CD40 ligand. CD40L (CD40L, CD154, gp39, and TRAM) belongs to the TNF gene family and is expressed more widely than CD40, predominantly on activated CD4+ T cells. Following interaction with CD40 ligand, CD40 mediates a number of major immunoregulatory functions, central to the control of thymus dependent humoral immunity and may be critical in the development of cell mediated immune responses. Other biological actions include B cell homotypic adhesion, proliferation, immunoglobulin isotype switch, and secretion. Activation of CD40 has also been shown to inhibit the growth of certain B cell lymphomas and to induce the death of transformed cells of mesenchymal or epithelial origin |
|||
Anti-LAMP3 antibody (Alexa-fluor 488) |
|||
| STJ170004 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
|||
Anti-LAMP3 antibody (Alexa-fluor 546) |
|||
| STJ170005 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
|||
Anti-LAMP3 antibody (Alexa-fluor 647) |
|||
| STJ170006 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The dendritic cell lysosomal-associated membrane protein (DC-LAMP)/CD208 is a type I integral transmembrane glycoprotein mostly homologous to CD68, of about 45 kDa in mouse and 90 kDa in human (glycosylation), with a bipartite C-terminal structure divided by a serine/proline rich region, a transmembrane domain and a conserved tyrosine-based lysosomal targeting motif in its cytoplasmic tail. Initially cloned as a specific marker of human mature dendritic cells (DCs), DC-LAMP has been subsequently shown to be expressed in alveolar type II pneumocytes. In both cell types, the molecule is found in the limiting membrane of intracellular multi-lamellar bodies, known as MIIC (MHC class II compartments) in human mature DCs and as lung surfactant-containing lamellar bodies in type II pneumocytes. In the latter cell type, DC-LAMP expression is also detected at the cell surface. |
|||
Anti-IL3RA antibody (Alexa-fluor 488) |
|||
| STJ170009 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
|||
Anti-IL3RA antibody (Alexa-fluor 546) |
|||
| STJ170010 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
|||
Anti-IL3RA antibody (Alexa-fluor 647) |
|||
| STJ170011 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: IL3 exerts its biologic activity through its interaction with a cell surface receptor that consists of two subunits. The a subunit (CD123) specifically binds IL3, whereas the ß subunit is required for signaling and is common to the GMCSFR and IL5-R. 107D2.08 and 106C2.02 mAbs were obtained after mouse immunization with sorted human tonsillar PDC. Both clones strongly stain PDCs and basophils, weakly stain monocytes, CD34+ derived DCs and CD11c+ DC, while no staining is observed on T, B, NK cells as well as on mono-derived DCs. Staining with 107D2.08 and 106C2.02 mAbs are maintained on sorted PDC cultured in the presence of IL3 and CD40L, but lost when IL3 alone is added to the culture. The recognition of the IL3Ra chain by 107D2.08 and 106C2.02 was confirmed by transfection studies. 107D2.08 appeared to be the most appropriate clone for in situ studies. 107D2.08 allowed the first observation of IL3Ra+ cells in breast tumor microenvironment |
|||
Anti-CD207 antibody (Alexa-fluor 488) |
|||
| STJ170014 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
|||
Anti-CD207 antibody (Alexa-fluor 546) |
|||
| STJ170015 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
|||
Anti-CD207 antibody (Alexa-fluor 647) |
|||
| STJ170016 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: Langerin/CD207 is a transmembrane C-type lectin receptor (CLR) of epidermal and mucosal Langerhans cells (LCs) that induces Birbeck's granule formation. Langerin features a single carbohydrate recognition domain (CRD) with mannose-type specificity in its extracellular portion. Langerin is unique among the CLRs in that it contains an intracellular domain with a proline-rich motif. Langerin expression has not been reported outside the DC system. (Valladeau J et al, 1999, Eur.J.Immunol., 29:2695-2704; Valladeau J et al, 2000 Immunity, 12 : 71-81; Kashihara M et al, 1986, J.Invest.Derm., 87 :602-607 Ito T et al, 1999, J.Immunol., 163 :1409-1419 ;Saeland S & Valladeau J, CD207 (Langerin) Workshop reports 2002, Leukocyte-Typing VII, White Cell Diff Antigens, D. Mason et al, Eds, Oxford University Press:306-307) |
|||
Anti-IL7R antibody (Alexa-fluor 488) |
|||
| STJ170020 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The IL7-R consists of 2 chains, IL-7R |
|||
Anti-IL7R antibody (Alexa-fluor 546) |
|||
| STJ170021 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The IL7-R consists of 2 chains, IL-7R |
|||
Anti-IL7R antibody (Alexa-fluor 647) |
|||
| STJ170022 | St John's Laboratory | 100 µg | EUR 393 |
|
Description: The IL7-R consists of 2 chains, IL-7R |
|||
Endoglin/CD105 Alexa Fluor |
|||
| FC15024 | Neuromics | 100 Tests | EUR 448 |
beta IV Tubulin antibody |
|||
| 22498-100ul | SAB | 100ul | EUR 390 |
Human Tubulin Beta 4(TUBb4)ELISA Kit |
|||
| QY-E01098 | Qayee Biotechnology | 96T | EUR 361 |
Anti-Hu CD16 Alexa Fluor® 488 |
|||
| A4-646-T100 | ExBio | 100 tests | EUR 269 |
Goat anti Mouse IgG1 (Alexa Fluor 488) |
|||
| 43R-1649 | Fitzgerald | 500 ug | EUR 570 |
|
Description: Goat anti Mouse IgG1 secondary antibody (Alexa Fluor 488) |
|||
Anti-gamma-Tubulin Alexa Fluor647 |
|||
| A6-465-C025 | ExBio | 0.025 mg | EUR 217 |
Anti-gamma-Tubulin Alexa Fluor647 |
|||
| A6-465-C100 | ExBio | 0.1 mg | EUR 394 |
SAM FCM (Alexa Fluor 647) |
|||
| abx098902-100tests | Abbexa | 100 tests | EUR 1233 |
SAM FCM (Alexa Fluor 488) |
|||
| abx098904-60tests | Abbexa | 60 tests | EUR 1358 |
EGFR antibody (Alexa Fluor 488) |
|||
| 61R-E109BAF | Fitzgerald | 125 ug | EUR 706 |
|
Description: Mouse monoclonal EGFR antibody (Alexa Fluor 488) |
|||
Mouse Tubulin beta- 4 chain, Tubb4 ELISA KIT |
|||
| ELI-53137m | Lifescience Market | 96 Tests | EUR 865 |
Bovine Tubulin beta- 4 chain, TUBB4 ELISA KIT |
|||
| ELI-29137b | Lifescience Market | 96 Tests | EUR 928 |
Human Tubulin beta- 4 chain, TUBB4 ELISA KIT |
|||
| ELI-13731h | Lifescience Market | 96 Tests | EUR 824 |
Rabbit Anti-Rat IgG (H+L)-Alexa 594 Fluor conjugate (adsorbed with human IgG) |
|||
| 50337 | Alpha Diagnostics | 0.5 ml | EUR 225 |
ELISA kit for Human Tubulin beta-4 chain (TUBB4) |
|||
| KTE60116-48T | Abbkine | 48T | EUR 332 |
|
Description: Quantitative sandwich ELISA for measuring Human Tubulin beta-4 chain (TUBB4) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
|||
ELISA kit for Human Tubulin beta-4 chain (TUBB4) |
|||
| KTE60116-5platesof96wells | Abbkine | 5 plates of 96 wells | EUR 2115 |
|
Description: Quantitative sandwich ELISA for measuring Human Tubulin beta-4 chain (TUBB4) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
|||
ELISA kit for Human Tubulin beta-4 chain (TUBB4) |
|||
| KTE60116-96T | Abbkine | 96T | EUR 539 |
|
Description: Quantitative sandwich ELISA for measuring Human Tubulin beta-4 chain (TUBB4) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
|||
Anti-Hu CD72 Alexa Fluor® 488 |
|||
| A4-310-T100 | ExBio | 100 tests | EUR 269 |
Anti-Bov CD9 Alexa Fluor® 488 |
|||
| A4-354-C100 | ExBio | 0.1 mg | EUR 269 |
Anti-Hu CD30 Alexa Fluor® 700 |
|||
| A7-455-T100 | ExBio | 100 tests | EUR 269 |
Anti-Hu CD94 Alexa Fluor® 700 |
|||
| A7-727-T100 | ExBio | 100 tests | EUR 269 |
Anti-Hu CD56 Alexa Fluor® 700 |
|||
| A7-789-T100 | ExBio | 100 tests | EUR 269 |
Donkey anti Goat IgG (H + L) (Alexa Fluor 647) |
|||
| 43R-ID028AF | Fitzgerald | 500 ug | EUR 430 |
|
Description: Donkey anti Goat IgG (H + L) secondary antibody (Alexa Fluor 647) |
|||
Donkey anti Chicken IgY (H + L) (Alexa Fluor 647) |
|||
| 43R-ID060AF | Fitzgerald | 300 ug | EUR 425 |
|
Description: Donkey anti Chicken IgY (H + L) (Fab'2) (Alexa Fluor 647) |
|||
Alpha Fluor™ 594 C5 Maleimide |
|||
| 1891 | AAT Bioquest | 1 mg | EUR 219 |
Streptavidin-Alexa594 (Alexas fluor 594) conjugate |
|||
| SV-A594-100 | Alpha Diagnostics | 100 tests | EUR 225 |
Goat Anti-Rabbit IgG(H+L) Alexa Fluor 647–conjugated |
|||
| S0013 | Affbiotech | 200ul | EUR 304 |
Goat Anti-Mouse IgG(H+L) Alexa Fluor 647–conjugated |
|||
| S0014 | Affbiotech | 200ul | EUR 304 |
Goat Anti-Mouse IgG(H+L) Alexa Fluor 488–conjugated |
|||
| S0017 | Affbiotech | 200ul | EUR 304 |
Goat Anti-Rabbit IgG(H+L) Alexa Fluor 488–conjugated |
|||
| S0018 | Affbiotech | 200ul | EUR 304 |
Alpha Fluor™ 532 acid [equivalent to Alexa Fluor™ 532 acid] |
|||
| 1795 | AAT Bioquest | 10 mg | EUR 393 |
Anti-beta-Tubulin Purified |
|||
| 11-251-C025 | ExBio | 0.025 mg | EUR 113 |
Anti-beta-Tubulin Purified |
|||
| 11-251-C100 | ExBio | 0.1 mg | EUR 186 |
Anti-beta-Tubulin Purified |
|||
| 11-427-C025 | ExBio | 0.025 mg | EUR 113 |
Anti-beta-Tubulin Purified |
|||
| 11-427-C100 | ExBio | 0.1 mg | EUR 186 |
Anti-beta-Tubulin Purified |
|||
| 11-444-C025 | ExBio | 0.025 mg | EUR 113 |
Anti-beta-Tubulin Purified |
|||
| 11-444-C100 | ExBio | 0.1 mg | EUR 186 |
Anti-Tubulin beta antibody |
|||
| STJ96145 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Beta tubulin is a protein encoded by the tubb gene which is approximately 49,7 kDa. Beta tubulin is localised to the cytoskeleton and cytoplasm. It is involved in the regulation of PLK1 activity at G2/M transition, development of Slit-Robo signalling, the innate immune system, cell cycle and organelle biogenesis and maintenance. Beta tubulin contains a highly acidic C-terminal region which can bind cations such as calcium. Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain and forms part of the cytoskeleton. Beta tubulin is ubiquitously expressed in the spleen, thymus and immature brain. Mutations in the tubb gene result in complex cortical dysplasia with other brain malformations. Mutations can also cause congenital symmetric circumferential, an autosomal dominant disease which results in multiple rings of folded skin mostly affecting the limbs. STJ96145 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. This polyclonal antibody detects endogenous levels of Tubulin beta protein. |
|||
Anti-Tubulin beta antibody |
|||
| STJ98436 | St John's Laboratory | 100 µl | EUR 234 |
|
Description: Mouse monoclonal to Tubulin beta. |
|||
Anti-Tubulin beta antibody |
|||
| STJ98566 | St John's Laboratory | 100 µl | EUR 234 |
|
Description: Mouse monoclonal to Tubulin beta. |
|||
Anti-beta-Tubulin antibody |
|||
| STJ99132 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Mouse monoclonal to beta-Tubulin. |
|||
Anti-beta-Tubulin antibody |
|||
| STJ99133 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Mouse monoclonal to beta-Tubulin. |
|||
Anti-beta-Tubulin antibody |
|||
| STJ96932 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Beta tubulin is a protein encoded by the tubb gene which is approximately 49,7 kDa. Beta tubulin is localised to the cytoskeleton and cytoplasm. It is involved in the regulation of PLK1 activity at G2/M transition, development of Slit-Robo signalling, the innate immune system, cell cycle and organelle biogenesis and maintenance. Beta tubulin contains a highly acidic C-terminal region which can bind cations such as calcium. Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain and forms part of the cytoskeleton. Beta tubulin is ubiquitously expressed in the spleen, thymus and immature brain. Mutations in the tubb gene result in complex cortical dysplasia with other brain malformations. Mutations can also cause congenital symmetric circumferential, an autosomal dominant disease which results in multiple rings of folded skin mostly affecting the limbs. STJ96932 was developed from clone 1E1-E8-H4 and was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. This antibody detects endogenous beta tubulin. |
|||
Anti-beta-Tubulin antibody |
|||
| STJ97016 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Mouse monoclonal to beta-Tubulin. |
|||
Anti-beta-tubulin antibody |
|||
| STJ97037 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Beta tubulin is a protein encoded by the tubb gene which is approximately 49,7 kDa. Beta tubulin is localised to the cytoskeleton and cytoplasm. It is involved in the regulation of PLK1 activity at G2/M transition, development of Slit-Robo signalling, the innate immune system, cell cycle and organelle biogenesis and maintenance. Beta tubulin contains a highly acidic C-terminal region which can bind cations such as calcium. Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain and forms part of the cytoskeleton. Beta tubulin is ubiquitously expressed in the spleen, thymus and immature brain. Mutations in the tubb gene result in complex cortical dysplasia with other brain malformations. Mutations can also cause congenital symmetric circumferential, an autosomal dominant disease which results in multiple rings of folded skin mostly affecting the limbs. STJ97037 was developed from clone M7. The antibody was affinity-purified from mouse ascites by affinity-chromatography using specific immunogen. The antibody detects endogenous beta tubulin. |
|||
Anti-beta-tubulin antibody |
|||
| STJ97041 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Mouse monoclonal to beta-tubulin. |
|||
Anti-beta Tubulin antibody |
|||
| STJ97131 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Rabbit polyclonal to beta Tubulin. |
|||
Anti-beta Tubulin antibody |
|||
| STJ13100428 | St John's Laboratory | 150 µl | EUR 427 |
Anti-Tubulin beta antibody |
|||
| STJ13100435 | St John's Laboratory | 500 µg | EUR 427 |
Anti-Beta-Tubulin antibody |
|||
| STJ16100474 | St John's Laboratory | 100 µg | EUR 406 |
Anti-Tubulin Beta antibody |
|||
| STJ31562 | St John's Laboratory | 200 µl | EUR 197 |
|
Description: Unonjugated rabbit polyclonal to tubulin beta |
|||
anti- Tubulin-beta antibody |
|||
| FNab09105 | FN Test | 100µg | EUR 548.75 |
|
Description: Antibody raised against Tubulin-beta |
|||
anti- Beta Tubulin antibody |
|||
| FNab09872 | FN Test | 100µg | EUR 548.75 |
|
Description: Antibody raised against Beta Tubulin |
|||
anti- beta Tubulin antibody |
|||
| FNab00879 | FN Test | 100µg | EUR 548.75 |
|
Description: Antibody raised against beta Tubulin |
|||
anti- Beta Tubulin antibody |
|||
| FNab00880 | FN Test | 100µg | EUR 548.75 |
|
Description: Antibody raised against Beta Tubulin |
|||
anti-beta-Tubulin (5G3) |
|||
| LF-MA20322 | Abfrontier | 100 ug | EUR 334 |
|
Description: Mouse monoclonal to betA tubulin |
|||
anti-beta-tubulin (M6) |
|||
| LF-MA20425 | Abfrontier | 100 ug | EUR 334 |
|
Description: Mouse monoclonal to Beta tubulin |
|||
anti-beta II tubulin |
|||
| LF-MA20432 | Abfrontier | 100 ug | EUR 334 |
|
Description: Mouse monoclonal to beta II tubulin |
|||
anti- Beta Tubulin antibody |
|||
| LSMab09872 | Lifescience Market | 100 ug | EUR 386 |
Anti-Beta-tubulin Antibody |
|||
| A1216-100 | Biovision | EUR 403 | |
anti-beta II Tubulin |
|||
| YF-PA23016 | Abfrontier | 100 ug | EUR 403 |
|
Description: Rabbit polyclonal to beta II Tubulin |
|||
anti-beta II Tubulin |
|||
| YF-PA25563 | Abfrontier | 50 ul | EUR 334 |
|
Description: Mouse polyclonal to beta II Tubulin |
|||
Anti-beta Tubulin antibody |
|||
| PAab00879 | Lifescience Market | 100 ug | EUR 386 |
Anti-Beta Tubulin antibody |
|||
| PAab00880 | Lifescience Market | 100 ug | EUR 386 |
alpha Tubulin (alpha Tubulin) Antibody (ATTO 594) |
|||
| abx446844-100ug | Abbexa | 100 ug | EUR 578 |
Anti-Hu CD3 zeta (pY153) Alexa Fluor® 488 |
|||
| A4-686-C100 | ExBio | 0.1 mg | EUR 269 |
Anti-Hu CD3 zeta (pY72) Alexa Fluor® 488 |
|||
| A4-712-C100 | ExBio | 0.1 mg | EUR 269 |
Anti-Hu CD3 zeta (pY142) Alexa Fluor® 488 |
|||
| A4-730-C100 | ExBio | 0.1 mg | EUR 269 |
Anti-Hu CD3 zeta (pY111) Alexa Fluor® 488 |
|||
| A4-737-C100 | ExBio | 0.1 mg | EUR 269 |
Anti-Hu CD3 zeta (pY153) Alexa Fluor® 647 |
|||
| A6-686-C100 | ExBio | 0.1 mg | EUR 269 |
Anti-Hu CD3 zeta (pY72) Alexa Fluor® 647 |
|||
| A6-712-C100 | ExBio | 0.1 mg | EUR 269 |
Anti-Hu CD3 zeta (pY142) Alexa Fluor® 647 |
|||
| A6-730-C100 | ExBio | 0.1 mg | EUR 269 |
Anti-Hu CD3 zeta (pY111) Alexa Fluor® 647 |
|||
| A6-737-C100 | ExBio | 0.1 mg | EUR 269 |
Ocena odpowiedzi immunogennej na nowatorską szczepionkę z koniugatem enterobaktyny u kurcząt do produkcji przeciwciał żółtka jaja specyficznych dla enterobaktyny
- Passive immunization with particular egg yolk antibodies (immunoglobulin Y, IgY) is rising as a promising various to antibiotics to manage bacterial infections. Lately, we developed a novel conjugate vaccine that might set off a robust immune response in rabbits directed towards enterobactin (Ent), a extremely conserved siderophore molecule utilized by completely different Gram-negative pathogens. Nevertheless, induction of Ent-specific antibodies seemed to be affected by the selection of animal host and vaccination routine.
- It’s nonetheless unknown if the Ent conjugate vaccine can set off a selected immune response in layers for the aim of manufacturing of anti-Ent egg yolk IgY. On this research, three hen vaccination trials with completely different regimens have been carried out to find out circumstances for environment friendly manufacturing of anti-Ent egg yolk IgY. Purified Ent was conjugated to 3 provider proteins, keyhole limpet hemocyanin (KLH), bovine serum albumin (BSA) and CmeC (a subunit vaccine candidate), respectively.
- Intramuscular immunization of Barred Rock layers with KLH-Ent conjugate 4 instances induced sturdy immune response towards entire conjugate vaccine however the titer of Ent-specific IgY didn’t change in yolk with solely a four fold improve detected in serum. Within the second trial, three completely different Ent conjugate vaccines have been evaluated in Rhode Island Crimson pullets with 4 subcutaneous injections. The KLH-Ent or CmeC-Ent conjugate persistently induced excessive degree of Ent-specific IgY in each serum (as much as 2,048 fold) and yolk (as much as 1,024 fold) in every particular person hen. Nevertheless, the Ent-specific immune response was solely quickly and reasonably induced utilizing a BSA-Ent vaccination.
- Within the third trial, ten White Leghorn layers have been subcutaneously immunized thrice with KLH-Ent, resulting in constant and robust immune response towards each entire conjugate and the Ent molecule in every hen; the imply titer of Ent-specific IgY elevated roughly 32 and 256 fold in serum and yolk, respectively. According to its potent binding to numerous Ent derivatives, the Ent-specific egg yolk IgY additionally inhibited in vitro progress of a consultant Escherichia coli pressure.
- Collectively, this research demonstrated that the novel Ent conjugate vaccine might induce sturdy, particular, and sturdy immune response in chickens. The Ent-specific hyperimmune egg yolk IgY has potential for passive immune intervention towards Gram-negative infections.
Korelacja odpowiedzi na szczepionki
Introduction: The humoral response to vaccinations varies extensively between people. There isn’t a information obtainable on the correlation between responses to completely different vaccines. On this research, we investigated the correlation of antibody responses between routine vaccine antigens in infants.
Strategies: One and 7 months after the 6-month vaccinations and one month after the 12-month vaccinations, antibody concentrations to diphtheria, tetanus, pertussis, polio (serotypes 1-3), Haemophilus influenzae sort b (Hib), pneumococcus (13 serotypes), meningococcus C, measles, mumps and rubella have been measured utilizing fluorescent bead-based multiplex immune-assays. For the correlation of antibody responses, Spearman’s rank correlation coefficients (ρ) with 95% confidence intervals (CI) have been calculated between responses to every vaccine antigen.
Outcomes: The correlation between concentrations of antibodies to the vaccinations ending at 6 months of age was greater one month in comparison with seven months after vaccination. The strongest correlations at each time factors have been noticed between antibody responses to completely different polio serotypes, sure pneumococcal serotypes and between responses to diphtheria and pneumococcal (conjugated to a diphtheria toxoid) vaccine antigens. Correlation between responses to tetanus, Hib, pertussis, polio and different vaccine antigens have been weak. The correlation between antibody responses to the 12-month vaccine antigens was weaker than to the 6-month vaccine antigens and there was a adverse correlation between responses to measles, mumps, rubella vaccine and non-live vaccine antigens (meningococcus C, tetanus and Hib). There was solely weak correlation between antibody responses to vaccines of the identical sort (e.g. conjugated polysaccharide or toxoid vaccines).
Conclusion: Correlation between antibody responses to related antigens in the identical vaccine (equivalent to completely different serotypes of a micro organism or virus), in addition to responses to antigens conjugated to related provider proteins, are sturdy. In distinction, correlation between responses to different vaccines are weak. Measuring antibody responses to at least one or a number of vaccine antigens subsequently doesn’t supply a dependable surrogate marker of responses to unrelated vaccines.
Nowatorski automatyczny check immunologiczny dla przeciwciał NY-ESO-1 i XAGE1 w surowicy w skojarzonym przewidywaniu odpowiedzi na terapię przeciw zaprogramowanej śmierci komórkowej – 1 w niedrobnokomórkowym raku płuca
Background: Anti-programmed cell death-1 (PD-1) antibodies (Abs) are key medication in non-small-cell lung most cancers (NSCLC) remedy; nonetheless, medical advantages with anti-PD-1 monotherapy are restricted. We reported that serum Abs towards cancer-testis antigens NY-ESO-1 and XAGE1 predicted medical advantages. We aimed to develop a totally automated immunoassay system measuring NY-ESO-1/XAGE1 Abs.
Strategies: Sera from 30 NSCLC sufferers earlier than anti-PD-1 monotherapy have been reacted with recombinant NY-ESO-1 protein- or artificial XAGE1 peptide-coated magnetic beads. ALP-conjugated Ab and chemiluminescent substrate have been added and luminescence measured. These procedures have been automated utilizing excessive sensitivity chemiluminescent enzyme immunoassay (HISCLTM). NY-ESO-1/XAGE1 Ab stability was examined beneath numerous circumstances. Response prediction accuracy was evaluated utilizing space beneath receiver working curve (AUROC).
Outcomes: HISCL detected particular serum NY-ESO-1/XAGE1 Abs, which ranges in ELISA and HISCL have been extremely correlated. The Ab ranges in HISCL have been secure at 4 temperatures, 5 freeze/thaw cycles, and long-term storage; the degrees weren’t interfered by frequent blood elements. The Ab ranges in 15 NSCLC responders to anti-PD-1 monotherapy have been considerably greater than these in non-responders and wholesome donors. The AUROC was the best (0.91; 95% CI, 0.78-1.0) in combinatory prediction with NY-ESO-1/XAGE1 Abs.
Conclusion: Our immunoassay system is beneficial to foretell medical advantages with NSCLC immune-checkpoint remedy.
